Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 8335  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
  » Next article
  » Previous article 
  » Table of Contents
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
  »  Article in PDF (291 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  References

 Article Access Statistics
    PDF Downloaded123    
    Comments [Add]    
    Cited by others 10    

Recommend this journal


Year : 2010  |  Volume : 58  |  Issue : 4  |  Page : 668-669

Coexistent of muscle specific tyrosine kinase and acetylcholine receptor antibodies in a myasthenia gravis patient

1 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
2 Department of Neurobiochemistry, All India Institute of Medical Sciences, New Delhi, India

Date of Acceptance24-Jun-2010
Date of Web Publication24-Aug-2010

Correspondence Address:
Madhuri Behari
Department of Neurology, All India Institute of Medical Sciences, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.68687

Rights and Permissions

How to cite this article:
Suhail H, Vivekanandhan S, Singh S, Behari M. Coexistent of muscle specific tyrosine kinase and acetylcholine receptor antibodies in a myasthenia gravis patient. Neurol India 2010;58:668-9

How to cite this URL:
Suhail H, Vivekanandhan S, Singh S, Behari M. Coexistent of muscle specific tyrosine kinase and acetylcholine receptor antibodies in a myasthenia gravis patient. Neurol India [serial online] 2010 [cited 2023 Mar 27];58:668-9. Available from: https://www.neurologyindia.com/text.asp?2010/58/4/668/68687


Myasthenia gravis (MG) is an autoimmune disorder with approximately 80-85% expressing antibodies against nicotinic acetylcholine receptors (nAChR-). [1] Of the seronegative MG patients, 40 -70% are positive for muscle specific tyrosine kinase antibodies (MuSK-Ab). [2] MuSK-Ab is usually positive in MG patients who are negative for AChR-Ab with progressive course, severe oculo-bulbar involvement, neck drop and respiratory muscle weakness. [3] Presence of both AChR-Ab and MuSK-Ab in the same MG patient is a very rare phenomenon.

A 31year-old female patient was first seen at another hospital in 2002, with 2 years history of intermittent bilateral ptosis, diplopia, proximal muscle weakness, easy fatigability, dysphagia, breathlessness, nasal regurgitation, slurred speech with nasal tone and neck muscle weakness. There was no family history of similar illness. The patient also had hypothyroidism and was on supplemental therapy. Repetitive nerve stimulation test (RNST) revealed decrement response but neostigmine test was negative. AChR and MuSK antibodies were not tested at that stage. Computerized tomographic scan of thorax showed evidence of thymic hyperplasia and thymectomy was done in 2002. The histopathology of thymus confirmed thymic hyperplasia. After thymectomy, the patient showed dramatic improvement in all the clinical symptoms except speech which continued to be slurred and nasal. She remained in remission for 6 years. In 2008, she presented to our neurology clinic facility with recurrence of symptoms, ptosis and diplopia. AChR and MuSK antibodies were tested on two separate occasions by radioimmunoassay method (RIA) using radio-receptor assay kit as per manufacturer's protocol, and she was detected positive for both the antibodies. [4] Her AChR-Ab titer was 2.47 and 1.45 nmol/L and MuSK-Ab titer was 2.23 and 1.75 nmol/L. She was treated with pyridostigmine 60 mg thrice daily with a satisfactory response.

This report presents a very rare patient of MG, who was positive for both AChR and MuSK antibodies. This is the only case in our records of more than 400 MG patients who tested positive for both AChR-Ab and MuSK-Ab. Literature survey revealed one such report who was positive for both AChR-Ab and MuSK-Ab, from UK by Al Saleh and Cariga in 2007. [5] Ohta et al. in 2004 reported MuSK-Abs in AChR-Ab seropositive MG patients, but later they withdrew the report because what they initially believed to be MuSK-Abs turned out to be antibodies to alkaline phosphatase. [6] Saulat et al. reported a case of MG, who was AChR-Ab positive and MuSK-Ab negative before thymectomy, but converted to MuSK-Ab positive and AChR-Ab negative after thymectomy. [7] The authors attributed this to "epitope spreading". Subsequent occurrence of both AChR-Ab and MuSK-Ab with disease relapse is considered to be due to epitope spreading, suggesting the spread of immunologic attack against AChR to include MuSK, with an altered pattern of autoimmune cross reactivity. [8] In experimental models of autoimmune diseases, the phenomenon of epitope spreading is well known. [9] However, in our case, it is difficult to say that this phenomenon of epitope spreading is applicable, since her earlier antibody status is not known. The first time we saw this patient was when she was almost 8 years into illness and after thymectomy with recurrence of symptoms. There is a small probability that relapse of disease may be due to reactivation and proliferation of lymphocytes in germinal hyperplasia after thymectomy. These autoreactive lymphocyte cells might have induced a distinct antibody response and the possibility of cross reacting epitopes happened. Coexistence of MuSK-Ab and AChR-Ab positivity in an MG patient suggests more severe and extensive range of clinical presentation. Additionally, AChR-Ab positive patients with MG should also be considered for MuSK antibody test for better prognosis and treatment.

 » References Top

1.Lindstrom J M. Acetylcholine receptors and myasthenia gravis. Muscle Nerve 2000;23:453-77.  Back to cited text no. 1      
2.Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-11.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403.   Back to cited text no. 4      
5.Al Saleh A, Cariga P. Myasthenia gravis with AChR and MuSK antibodies positivity: Case report. Clin Neurophysiol 2007;118:e165.  Back to cited text no. 5      
6.Ohta K, Shigemoto K, Kubo S, Maruyama N, Abe Y, Ueda N, et al. MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase. Neurology 2005;65:1988.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]  
7.Saulat B, Maertens P, Hamilton WJ, Bassam BA. Anti-MuSk antibody after thymectomy in a previously seropositive myasthenic child. Neurology 2007;69:803-4.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]  
8.Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D. Determinant spreading and immune responses to acetylcholine receptors un myasthenia gravis. Immunol Rev 1998;164:157-68.  Back to cited text no. 8  [PUBMED]    
9.Vanderlugt CL, Miller SD. Epitope spreading in immune mediated disease: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]  

This article has been cited by
1 A very late onset AChR and MuSK double positive myasthenia gravis: a case description and literature review.
A. Pugliese, G. Nicocia, S. Messina, A. Toscano, C. Rodolico
Neuromuscular Disorders. 2022;
[Pubmed] | [DOI]
2 AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?
Jieni Zhang, Yin Chen, Jiaxin Chen, Xin Huang, Haiyan Wang, Yan Li, Weibin Liu, Huiyu Feng
Neurological Sciences. 2021; 42(3): 863
[Pubmed] | [DOI]
3 AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review
Yaru Lu, Hao Ran, Wenhao Yang, Qian Ma, Li Qiu, Changyi Ou, Pei Chen, Zhongqiang Lin, Weibin Liu
Neuromuscular Disorders. 2020; 30(7): 534
[Pubmed] | [DOI]
4 AChR-myasthenia gravis switching to double-seropositive several years after the onset
Vasiliki Zouvelou,Paraskevi Zisimopoulou,Erasmia Psimenou,Eirini Matsigkou,Eleftherios Stamboulis,Socrates J. Tzartos
Journal of Neuroimmunology. 2014; 267(1-2): 111
[Pubmed] | [DOI]
5 Double-seropositive myasthenia gravis
Vasiliki Zouvelou,Stavroula Kyriazi,Michael Rentzos,Maria Belimezi,Maria-Angeliki Micheli,Socrates J. Tzartos,Eleftherios Stamboulis
Muscle & Nerve. 2013; 47(3): 465
[Pubmed] | [DOI]
6 Double-seropositive myasthenia gravis
Zouvelou, V. and Kyriazi, S. and Rentzos, M. and Belimezi, M. and Micheli, M.-A. and Tzartos, S.J. and Stamboulis, E.
Muscle and Nerve. 2013; 47(3): 465-466
7 Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine
Poulas, K. and Koutsouraki, E. and Kordas, G. and Kokla, A. and Tzartos, S.J.
Journal of Neuroimmunology. 2012; 250(1-2): 94-98
8 Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine
Konstantinos Poulas,Euphrosyni Koutsouraki,Gregory Kordas,Anna Kokla,Socrates J. Tzartos
Journal of Neuroimmunology. 2012; 250(1-2): 94
[Pubmed] | [DOI]
9 Treatment of anti-MuSK antibody positive myasthenia gravis | [A MuSK-ellenes antitest pozitív myasthenia gravis kezelése]
Pál, Z., Boczán, J., Bereznai, B., Lovas, G., Molnár, M.J.
Orvosi Hetilap. 2011; 152(39): 1586-1589
10 A MuSK-ellenes antitest pozitív myasthenia gravis kezelése
Zsuzsanna Pál,Judit Boczán,Benjamin Bereznai,Gábor Lovas,Mária Judit Molnár
Orvosi Hetilap. 2011; 152(39): 1586
[Pubmed] | [DOI]


Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow